DoMore Diagnostics is on a mission to transform cancer diagnostics with artificial intelligence to improve patient care and make drug development more effective. We use state-of-the-art methods to improve patients’ quality of life and help clinicians make more informed decisions. Our technology is based on pioneering research on utilizing artificial intelligence to increase the prognostic value from routine clinical pathology cancer tissue samples. The extensive research conducted at top universities (University in Oslo, Oxford University and University College of London) has been published in leading and high impact scientific journals such as The Lancet and Nature Reviews Cancer. These new methods have resulted in fully automated histotyping that provide objective and precise prognostic information that correlate and out-perform existing markers. This novel histotyping can guide selection of therapy to avoid over- and undertreatment. It can also make cancer drug development more effective by ensuring more precise diagnosis and prognosis, which is the fundament for precision medicine. Artificial intelligence is set for a breakthrough in medicine and several megatrends are pushing for new solutions in cancer diagnostics. Digital pathology and new AI algorithms will play a significant role in the future of medicine and hold multiple commercial opportunities. DoMore Diagnostics is at the forefront of the field and will bring these next generation products to the clinic.